The combination of HIV proteins Tat and Nef is chemotactic for CD4+ cells. Utilizing the capacity of Tat and Nef to modulate CD4+ cell trafficking and infiltration, the invention provides various treatment modes for individuals infected with HIV. The invention further provides treatment modes for other localized diseases by controlling CD4+ cell trafficking and infiltration. In particular, the invention provides methodology for promoting CD4+ cell chemotaxis to a localized site of infection as a means of augmenting the efficacy of extant chemotherapeutic methods. The invention further provides methodology for diverting CD4+ cell infiltration from a localized site where the presence of CD4+ cells is detrimental to the clinical outcome, by providing a composition comprising Tat and Nef at a distinct site, such as blood, within the individual where the accumulation of CD4+ cells is less detrimental.
Patent
HIV-encoded chemoattractant
United States Patent and Trademark Office
02/26/2008
PDM V1.0, Open Access
Abstract
Details
- Title: Subtitle
- HIV-encoded chemoattractant
- Creators
- David R Soll (Inventor)Damon Shutt (Inventor)
- Contributors
- University of Iowa Research Foundation (Iowa City, IA, US) (Assignee)
- Resource Type
- Patent
- Publisher
- United States Patent and Trademark Office; United States
- Patent
- US Patent 7,335,365; United States Patent and Trademark Office (United States, Alexandria) - USPTO; Published; 11/078,729; 03/14/2005
- Number of pages
- 15 pages
- Language
- English
- Date published
- 02/26/2008
- Academic Unit
- UI Research Foundation
- Record Identifier
- 9983761961702771
Metrics
12 File views/ downloads
12 Record Views